Title:
HETEROCYCLIC ACETIC ACID AMIDE COMPOUND
Document Type and Number:
WIPO Patent Application WO/2014/171528
Kind Code:
A1
Abstract:
[Problem] To provide a compound of formula (I) that is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM). [Solution] The inventors studied a compound that has a dopamine D1 receptor positive allosteric modulating action and is useful as an active ingredient for a pharmaceutical composition for preventing and/or treating cognitive dysfunction, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug dependence, etc., have verified that a heterocyclic acetic acid amide compound has a dopamine D1 receptor positive allosteric modulating action, and have completed the present invention. This heterocyclic acetic acid amide compound has a dopamine D1 receptor positive allosteric modulating action and may be used as a preventive and/or therapeutic agent for cognitive dysfunction, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug dependence, etc.
Inventors:
SHIRAKI RYOTA (JP)
TOBE TAKAHIKO (JP)
KAWAKAMI SHIMPEI (JP)
MORITOMO HIROYUKI (JP)
OHMIYA MAKOTO (JP)
TOBE TAKAHIKO (JP)
KAWAKAMI SHIMPEI (JP)
MORITOMO HIROYUKI (JP)
OHMIYA MAKOTO (JP)
Application Number:
PCT/JP2014/061007
Publication Date:
October 23, 2014
Filing Date:
April 18, 2014
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
C07D413/12; C07D403/12; C07D417/12; A61K31/423; A61K31/428; A61K31/498; A61P25/14; A61P25/16; A61P25/28; A61P25/36
Domestic Patent References:
WO2005080334A1 | 2005-09-01 | |||
WO2008011551A1 | 2008-01-24 | |||
WO2003077847A2 | 2003-09-25 | |||
WO2005118561A1 | 2005-12-15 | |||
WO2000059905A1 | 2000-10-12 |
Foreign References:
JP2008500300A | 2008-01-10 | |||
JP2002541151A | 2002-12-03 | |||
JP2005519958A | 2005-07-07 | |||
JP2009544623A | 2009-12-17 | |||
JP2010529051A | 2010-08-26 |
Other References:
MEDICINAL RESEARCH REVIEWS, vol. 29, no. 2, 2009, pages 272 - 294
NATURE, vol. 385, no. 6617, 13 February 1997 (1997-02-13), pages 634 - 636
EUROPEAN NEUROPSYCHOPHARMCOLOGY, vol. 19, no. 6, 2009, pages 440 - 450
PSYCHOPHARMACOLOGY, vol. 210, no. 3, 2010, pages 407 - 418
MOLECULAR PHARMACOLOGY, vol. 71, no. 6, 2007, pages 1598 - 1609
THE AMERICAN JOURNAL OF PSYCHIATRY, vol. 159, no. 5, 2002, pages 761 - 767
PHARMACOPSYCHIATRY, vol. 39, no. 3, 2006, pages 115 - 116
CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 2, no. 11, 2001, pages 1582 - 1591
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 5, 2011, pages 3270 - 3276
NEURODEGENERATIVE DISEASES, vol. 8, no. 4, 2011, pages 230 - 239
NEUROSCIENCE LETTERS, vol. 513, no. 2, 2012, pages 214 - 218
NEUROPSYCHOLOGIA, vol. 51, no. 2, 2013, pages 235 - 266
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 345, no. 21, 2001, pages 1548
CLINICAL NEUROPHARMACOLOGY, vol. 21, no. 6, 1998, pages 339 - 343
ACS CHEMICAL BIOLOGY, vol. 3, no. 9, 2008, pages 530 - 541
BRITISH JOURNAL OF PHARMACOLOGY, vol. 165, no. 6, 2012, pages 1659 - 1669
PROG. MED., vol. 5, 1985, pages 2157 - 2161
"Molecular Design", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Pharmaceutical Research and Development", pages: 163 - 198
P. G. M. WUTS; T. W. GREENE: "Greene's Protective Groups in Organic Synthesis", 2006
S. R. SANDLER; W. KARO: "Organic Functional Group Preparations", vol. 1, 1991, ACADEMIC PRESS INC.
"Courses in Experimental Chemistry", vol. 16, 2005, MARUZEN
"Greene's Protective Groups in Organic Synthesis", 2006
See also references of EP 2987793A4
NATURE, vol. 385, no. 6617, 13 February 1997 (1997-02-13), pages 634 - 636
EUROPEAN NEUROPSYCHOPHARMCOLOGY, vol. 19, no. 6, 2009, pages 440 - 450
PSYCHOPHARMACOLOGY, vol. 210, no. 3, 2010, pages 407 - 418
MOLECULAR PHARMACOLOGY, vol. 71, no. 6, 2007, pages 1598 - 1609
THE AMERICAN JOURNAL OF PSYCHIATRY, vol. 159, no. 5, 2002, pages 761 - 767
PHARMACOPSYCHIATRY, vol. 39, no. 3, 2006, pages 115 - 116
CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 2, no. 11, 2001, pages 1582 - 1591
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 5, 2011, pages 3270 - 3276
NEURODEGENERATIVE DISEASES, vol. 8, no. 4, 2011, pages 230 - 239
NEUROSCIENCE LETTERS, vol. 513, no. 2, 2012, pages 214 - 218
NEUROPSYCHOLOGIA, vol. 51, no. 2, 2013, pages 235 - 266
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 345, no. 21, 2001, pages 1548
CLINICAL NEUROPHARMACOLOGY, vol. 21, no. 6, 1998, pages 339 - 343
ACS CHEMICAL BIOLOGY, vol. 3, no. 9, 2008, pages 530 - 541
BRITISH JOURNAL OF PHARMACOLOGY, vol. 165, no. 6, 2012, pages 1659 - 1669
PROG. MED., vol. 5, 1985, pages 2157 - 2161
"Molecular Design", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Pharmaceutical Research and Development", pages: 163 - 198
P. G. M. WUTS; T. W. GREENE: "Greene's Protective Groups in Organic Synthesis", 2006
S. R. SANDLER; W. KARO: "Organic Functional Group Preparations", vol. 1, 1991, ACADEMIC PRESS INC.
"Courses in Experimental Chemistry", vol. 16, 2005, MARUZEN
"Greene's Protective Groups in Organic Synthesis", 2006
See also references of EP 2987793A4
Attorney, Agent or Firm:
MORITA, Hiroshi et al. (JP)
Morita 拓 (JP)
Morita 拓 (JP)
Download PDF:
Previous Patent: NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY
Next Patent: NOVEL POLYCARBOXYLIC ACID ANHYDRIDE AND USE THEREOF
Next Patent: NOVEL POLYCARBOXYLIC ACID ANHYDRIDE AND USE THEREOF